Mihran H. Shirinian
Experienced in Parapneumonic Pleural Effusion

Dr. Mihran H. Shirinian

Hematology
1505 Wilson Terr, Ste 340, 
Glendale, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Parapneumonic Pleural Effusion
1505 Wilson Terr, Ste 340, 
Glendale, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

To provide state of the art medical care for our patients in a friendly, and compassionate setting.

Dr. Shirinian is rated as an Experienced provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Acute Erythroid Leukemia (AEL), Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Cairo University
Specialties
Hematology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Medical Oncology)
Internal Medicine
Hospital Affiliations
Keck Hospital Of USC
Glendale Adventist Medical Center
Languages Spoken
English
Arabic
Armenian
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Comprehensive Oncology Hematology Center
1505 Wilson Terr, Ste 340, Glendale, CA 91206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Journal: International journal of colorectal disease
Published: December 24, 2023
Similar Doctors
Advanced in Parapneumonic Pleural Effusion
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology
Advanced in Parapneumonic Pleural Effusion
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (4.9 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Kim is a Hematologist Oncology specialist and an Oncologist in South Pasadena, California. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Stomach Cancer, Chronic Familial Neutropenia, Agranulocytosis, and Blood Clots.

Experienced in Parapneumonic Pleural Effusion
Dr. Kalust Ucar
Hematology
Experienced in Parapneumonic Pleural Effusion
Dr. Kalust Ucar
Hematology

Kalust Ucar, MD Private Practice

222 W Eulalia St, Ste 100B, 
Glendale, CA 
 (2.2 miles away)
818-637-7611
Languages Spoken:
English, Armenian, French, Portuguese, Spanish
See accepted insurances
Offers Telehealth

Kalust Ucar is a Hematologist in Glendale, California. Dr. Ucar is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Ronald Tang
Experienced in Parapneumonic Pleural Effusion
Dr. Ronald Tang
Oncology | Hematology
Experienced in Parapneumonic Pleural Effusion
Dr. Ronald Tang
Oncology | Hematology

Los Angeles Cancer Network

50 Alessandro Place, Ste 310 South Tower, 
Pasadena, CA 
 (4.7 miles away)
626-288-0008
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Tang is a Hematologist and an Oncologist in Pasadena, California. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Parapneumonic Pleural Effusion. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Neuroendocrine Carcinoma of the Cervix, and Cervical Cancer. Dr. Tang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shirinian's expertise for a condition
ConditionClose
    View All 30 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile